Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.
Euro Surveill. 2023 Jul;28(27). doi: 10.2807/1560-7917.ES.2023.28.27.2200773.
Infections with OXA-244-carbapenemase-producing with sequence type (ST)38 have recently increased in Europe. Due to its low-level activity against carbapenems, OXA-244 can be difficult to detect. Previous assessments have not revealed a clear source and route of transmission for OXA-244-producing , but there are indications of non-healthcare related sources and community spread. Here we report a hospital-associated outbreak of OXA-244-producing ST38 involving three hospitals in Western Norway in 2020. The outbreak occurred over a 5-month period and included 12 cases identified through clinical (n = 6) and screening (n = 6) samples. The transmission chain was unclear; cases were identified in several wards and there was no clear overlap of patient stay. However, all patients had been admitted to the same tertiary hospital in the region, where screening revealed an outbreak in one ward (one clinical case and five screening cases). Outbreak control measures were instigated including contact tracing, isolation, and screening; no further cases were identified in 2021. This outbreak adds another dimension to the spread of OXA-244-producing ST38, illustrating this clone's ability to establish itself in the healthcare setting. Awareness of challenges concerning OXA-244-producing diagnostic is important to prevent further spread.
最近,欧洲产 OXA-244-碳青霉烯酶的 感染病例数量有所增加,其对碳青霉烯类药物的低活性使其难以检测。之前的评估并未揭示出产 OXA-244 的明确来源和传播途径,但有迹象表明其存在非医疗相关来源和社区传播。在此,我们报告了 2020 年挪威西部三家医院发生的 OXA-244 产 ST38 医院相关暴发事件。该暴发持续了 5 个月,通过临床(n=6)和筛查(n=6)样本共发现 12 例病例。传播链不明确;病例分布在多个病房,且患者入住时间没有明显重叠。然而,所有患者都曾在该地区的同一家三级医院接受治疗,筛查在该医院的一个病房发现了暴发(1 例临床病例和 5 例筛查病例)。随后采取了包括接触者追踪、隔离和筛查在内的暴发控制措施;2021 年未再发现新病例。该暴发事件为产 OXA-244 的 ST38 的传播增加了新的维度,表明该克隆有能力在医疗保健环境中立足。了解产 OXA-244 诊断方面的挑战对于防止进一步传播非常重要。